Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China. (linkinghub.elsevier.com)

Authors: Hong S … Yang Y Journal: The Lancet Published: 2026-10-26 DOI: https://doi.org/10.1016/S0140-6736(26)02026-X